By: Linda Flegge
Prime Medicine ( NYSE:PRME – Free Report had its price objective cut by Chardan Capital from $17.00 to $15.00 in a research report report published on Wednesday morning, Benzinga reports.
Linda Flegge is a financial journalist specializing in stock market news and analysis. With a focus on companies listed on the NASDAQ and NYSE, Linda provides insights into stock positions, share sales, and stock holdings of various investment firms. Her articles cover a range of industries, including technology, energy, and retail.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Linda Flegge's coverage primarily focuses on investment analysis and cites data extensively. She appears to center her reporting around the finance, stock market, investment, wealth management, and companies' themes.
Given this focus, Linda is likely interested in pitches that provide unique insights or analysis related to investments, stock market trends, financial data interpretation, or wealth management strategies. Those with access to valuable industry data or expertise in interpreting financial trends may find success when reaching out to Linda.
It's important for potential sources approaching Linda to have a strong grounding in quantitative analysis and an ability to draw actionable insights from financial data.
This information evolves through artificial intelligence and human feedback. Improve this profile .